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Introduction: A paradigm shift in breast cancer was introduced by Sørlie's concept of intrinsic subtypes
[1]. We validated this concept e which was originally based on 84 individuals e in a large cohort study
of 1035 patients with oncoplastic surgery and analyzed if early and late recurrences are linked to a
speciﬁc intrinsic tumor subtype or resection margins.
Materials and methods: 1035 patients with oncoplastic surgery (2004e2009) were analyzed with regard
to treatment characteristics and patterns of early (<5 years) and late recurrence (>5 years) and survival
related to the intrinsic subtypes. Data was retrieved from patient's charts, customized patients ques-
tionnaires and cancer registries.
Results: 944 patients with primary, unilateral breast cancer, median age 58 years, were eligible for
analysis. At a median FU of 5.2 years, LRR was 4.0%, 5-year-OS 94.5% and DFS 90.9%. Intrinsic subtypes,
but not T-size, nodal-status, resections margins nor histopathology, governed local control and survival.
There was no signal for prevelance of unclear margins in any of intrinsic subgroups and no preference of
any oncoplastic technique attributed to them. TNBC and Her2 non-luminal breast cancer had highest
recurrence and lowest survival rates. Although sentinel involvement (SLNþ) was prevailing in the
Luminal-B-Her 2 negative subtype at 34.3%, this did not translate into a higher axillary dissection rate.
Conclusion: This study conﬁrmed the intrinsic subtype concept on a large clinical basis and describes the
patterns of early and late recurrence in oncoplastic surgery, concluding that bigger risk may not be
overcome by bigger surgery.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Various oncoplastic techniques have evolved in the last de-
cades and former concepts attributed high oncologic safety to a
high extent of surgery in breast cancer (BC). Determinants of local
control were mainly considered to be T-size, resection margins
and nodal status until the intrinsic subtype concept by Sorlie T.Luisenkrankenhaus, Director:
üsseldorf, Germany. Tel.: þ49
74499.
Ltd. This is an open access article uet al. in 2001 has been introduced [1]. In this study, we investi-
gated different surgical techniques in relation to intrinsic sub-
types, as each of these subtypes yields different recurrence rates.
This may lead to surgeons' assumption that also clinico-
pathological features of these subtypes may vary in the sense of
higher occurence of multicentricity, presence of unclear margins,
re-excision rate and nodal involvement. Surgeons may be temp-
ted to try to overcome “bigger risk” by applying “bigger surgery”
[2], with a predilection for bigger margins or mastectomy in high-
risk intrinsic subtypes. The question remained whether re-
currences occur due to intrinsic biology and/or unclear margins
and whether tumor biology may be overturned by applying
extensive surgery as postulated by the Halstedian dogma in the
last century. Sorlie's milestone paper was originally based on ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient characteristics.
Characteristics Number of patients Percentage (%) of n ¼ 944
Age
<30 years 7 0.7
30e39 years 41 4.3
40e49 years 190 20.1
50e59 years 261 27.7
60e69 years 305 32.3
70e79 years 128 13.6
80 years 12 1.3
T-size
Tis 110 11.7
T1mic 4 0.4
T1a 28 3.0
T1b 113 12.0
T1c 417 44.2
T2 209 22.1
T3 3 0.3
T4 3 0.3
Unknown 57 6.0
Nodal status
N0 665 70.4
N1 24 2.5
N1a 109 11.6
N2 0 0
N2a 34 3.6
N3 0 0
N3a 10 1.1
Unknown 102 10.8
Grading
G1 97 10.3
G2 620 65.7
G3 201 21.3
Unknown 26 2.7
Resection margin
R0 910 96.4
R1 14 1.5
Unknown 20 2.1
Histology
Invasive ductal 572 60.6
Invasive lobular 110 11.6
Invasive with other Histology 129 13.7
Non-invasive 110 11.7
Unknown 23 2.4
Fig. 1. Distribution of tumor locations in the breast.
M. Rezai et al. / The Breast 24 (2015) 384e390 385cohort of 84 patients [1]. We translated this concept into a cohort
of more than 1000 oncoplastic patients in order to analyze
whether this concept may be conﬁrmed in the framework of
oncoplastic techniques and if oncoplastic breast conserving
techniques are valid options for dealing with all intrinsic sub-
types at a high degree of local and systemic control. We assessed
recurrence rates (early: <5 years, late: > 5 years), DFS and OS and
related it to intrinsic subtypes, grading, T-size, nodal-status,
resection margins and histopathological subtypes.
Patients and methods
Patient cohort
A total of 1035 patients with BC and oncoplastic surgery from
2004 to 2009 were identiﬁed for this study. Inclusion criteria
were unilateral, non-metastasized primary BC and 944 patients
ﬁnally fulﬁlled these criteria. Patient and treatment characteris-
tics as well as survival data were retrieved from patient records,
customized questionnaires and cancer registries. The study was
approved by the institutional review board and complied with
the declarations of Helsinki and the principles of good clinical
practice.
Tumor classiﬁcation
Tumors were classiﬁed according to TNM-system [3] and
analyzed in a central pathology. Grading was classiﬁed according to
Elston and Ellis [4]. ER and PR status of BC specimen included in our
study were considered as positive if 10% of BC cells expressed ER
and/or PR, in accordance with the AGO and ASCO/CAP guidelines at
the time of patient enrollment for treatment [5,6]. Her2-status was
considered as positive if DAKO-Score was 3þ or FISH-analysis was
positive in DAKO-Score 2þ [6].
As Ki-67 was not available for all patients of the cohort, we used
2011 St. Gallen International Expert Consensus Guidelines to clas-
sify histological approximated intrinsic subtypes: luminal A (ER þ
and/or PRþ, ERBB2, grade 1/2), luminal B HER2 negative (ERþ and/
or PRþ, ERBB2, grade 3), luminal B HER2 positive (ERþ and/or PRþ,
ERBB2þ), HER2 non luminal (ER and PR, ERBB2þ, all grades) or
TNBC (ER and PR, ERBB2) [7].
Statistics
Data was entered into a Microsoft Ofﬁce Excel 2007 database,
and analyses were performed using SAS Version 9.2. Local control
parameters were calculated in a univariate and multiple analysis.
All patient characteristics were presented in frequency tables and
compared by univariate testing (Wilcoxon rank sum and chi-
square tests). Patient numbers refer to a total of 944; calcu-
lating percentages includes missings. Survival was estimated and
plotted by using KaplaneMeier analysis. Log-rank test and
Wilcoxon-rank sum tests were used. Multiple Cox proportional
hazards regression models were used for estimating age-adjusted
hazard ratios (HR) with 95% conﬁdence intervals (95% CI). All p-
values were given descriptively without further adjustment for
multiple testing.
Results
Patients baseline characteristics
A total of 944 patients met inclusion criteria. 70.7% was the
questionnaire response rate. Median follow-up was 5.2 years.Average age was 57.6 years (median 58, range 25e88 years)
(Table 1).
Tumor localisation
The most common tumor localization was the upper outer
quadrant with 36.5% (Fig. 1.), 11.7% were multifocal or multicentric.
Fig. 3. Oncoplastic surgical techniques.
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Invasive BC was the most common histology (þ/ non-invasive
component): 60.6% invasive-ductal BC, 11.6% invasive-lobular (ILC)
and 9.4% invasive-tubulo-ductal (ITD) or lobular-ductal (LDC). Only
11.7% (n ¼ 110) have been classiﬁed as non-invasive BC with 95.5%
as DCIS and 2.7% as CLIS. Hormone receptor (HR) was positive in
82.5% and Her2-receptor in 14.2%. Luminal A was the predominant
subtype (62.6%). Fig. 2 displays the distribution of approximated
intrinsic subtypes.
Tumor and treatment characteristics of intrinsic subgroups
Although the rate of sentinel involvement (SLNþ) was highest in
the Luminal B Her 2 negative subtype at 34.3%, this was not re-
ﬂected in a higher axillary dissection rate which was at 23.3%
comparable to all other subtypes. As we determined intrinsic
subtypes along histopathological approximation and used grading
as a tool according to St. Gallen 2011 guidelines, only the distri-
bution of grading in TNBC and Her2 subtypes are reported here. We
found grade 3 in TNBC with 54.6% and in Her2 non luminal subtype
with 66.7%. In Luminal B Her2 positive 56.3% were grade 2 and
32.5% grade 3 (p < 0.0001). There was no signal of over-
representation of any subtype in the group of tumors with un-
clear margins (n ¼ 108). The majority (89.8%) opted for re-excision
e only 14 cases remained with unclear margins (1.5% of whole
cohort).
T-size at diagnosis varied within the intrinsic subtype groups
with Luminal B Her2 negative at greatest tumor size. We did not
detect any differences in type of surgery related to intrinsic
subtypes.
TNBC occurred more often in younger women aged <40 years
with 21.0% compared with older patients (50e59 years 10% and
60e69 years 8%). Frequency of Luminal A increased with age: 73%
were older than 70 years old versus 38% aged<40 years (p¼ 0.008).
Treatment characteristics
Surgery
Glandular rotation mammaplasty (63.8%) and tumor-site-
adapted reduction mammaplasty (20.9%) were the most frequent
oncoplastic techniques (Fig. 3). The median resection volume was
32 g (range 11e793 g). A secondary mastectomy as subsequent
surgery was necessary only in 7.2% (multicentricity, extensive tu-
mor size or repeatedly unclear margins).Fig. 2. Histopathologically approximated intrinsic subtypes.Systemic therapy
Information on chemotherapy was available in 76.1%, out of
which 25.3% underwent adjuvant chemotherapy, 20.2% neo-
adjuvant chemotherapy and 3.5% both of them. Endocrine therapy
was prescribed for all ERþ/PR þ cases and continued by 62.2%.Patterns of recurrence e LRR, DFS and OS according to tumor
biology and type of surgery
At a median follow-up of 5.2 years, 38 out of 944 patients (4.0%;
95% CI 2.8%e5.5%) had a local recurrence (range 0.1e8.6 years);
most of them (n ¼ 34) in the ﬁrst 5 years after diagnosis, only in 4
cases the recurrence appeared after a follow-up of 5 years. At 5
years, DFS was 90.9% and OS 94.5% (see Table 2).
TNBC had highest LRR (11.3%) followed by Her2 non-luminal
subtype with 9.3%. Recurrences occurred in lateral thoracic wall
advancement at 7.1%, glandular rotation mammaplasty at 3.8%,
dermoglandular rotation mammaplasty at 4.8% and tumor-adapted
reduction mammaplasty at 3.6%. However, there was no signiﬁcant
difference in recurrence rates as to the type of oncoplastic surgery.
(p ¼ n.s.).Age and recurrence
Recurrence rates and survival did not vary signiﬁcantly with
age: patients aged < 40 years experienced a local recurrence with a
rate of 8.3% (95%CI 2.3%e20%) compared with patients
aged  40 years at 3.8% (95%CI 2.7%-5.4%, (p > 0.05)). OS was 95.3%
vs. 94.5% (p > 0.05), and 5 y-DFS was 92.7% vs. 95.9% (p > 0.05) (see
Fig. 4).T-size
The recurrence of non-invasive BC was 6.4% versus 3.7% in
invasive BC (p ¼ 0.17). Recurrence rate of pT1a-tumors was 7.1%. Of
note, all recurrences in this group were associated with high grade,
triple-negative and Her2 non-luminal breast cancer. DFS and OS
was: T1a 92.9% and 100%, T1b 94.4% and 95.3%, T1c 91.8% and 95.2%,
T2 87.3% and 91.9%. Low representation of Tmic, T3 and T4 cases did
not allow statistical comparison of these groups. Tumor size did not
have a signiﬁcant impact on LRR (p ¼ 0.12) or survival (p > 0.05) in
this cohort of predominantly T1/T2 tumors.
Table 2
Tumor characteristics of recurrence (n ¼ 38).
Tumor characteristics of recurrence (n ¼ 38) Recurrence (n ¼ 38)
No. %
DCIS n ¼ 8 21.1
Invasive-ductal n ¼ 20 52.6
Invasive-lobular n ¼ 4 10.4
Other n ¼ 6 15.9
Unknown n ¼ 0 0.0
Her2 non luminal n ¼ 5 13.1
Luminal A n ¼ 13 34.2
Luminal B Her2 negative n ¼ 2 5.3
Luminal B Her2 positive n ¼ 3 7.9
triple-negative n ¼ 11 29.0
Unknown n ¼ 4 10.5
Tis n ¼ 7 18.4
T1a n ¼ 2 5.3
T1b n ¼ 2 5.3
T1c n ¼ 15 39.4
T2 n ¼ 9 23.7
T3 n ¼ 3 7.9
T4 n ¼ 0 0.0
Unknown n ¼ 0 0.0
N0 n ¼ 21 28.9
Nþ n ¼ 9 15.8
Unknown n ¼ 8 55.3
G1 n ¼ 0 0.0
G2 n ¼ 21 55.3
G3 n ¼ 14 35.8
Unknown n ¼ 3 7.9
Fig. 4. Recurrence rate according to age groups: exact 95% conﬁdence interval around
proportion.
Table 3
Recurrence rate, DFS and OS related to nodal status (%).
Nodal status Number of patients Recurrence rate 5-Years DFS % 5-Years OS%
N0 665 21 (3.2%) 92.4 95.7
N1 24 2 (8.3%) 87.3 91.5
N1a 109 5 (4.6%) 89.3 92.0
N2a 34 0 (0.0%) 81.5 81.5
N3a 10 2 (20.0%) 70.0 90.0
Unknown 102
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Nodal negative disease (N0) and low lymphatic involvement
(N1) did not yield signiﬁcant differences in LRR (p ¼ 0.23), OS
(p ¼ 0.2) or DFS (p ¼ 0.28).
In nodal stage N2a, we detected a signiﬁcant lower OS compared
to N0 (81.5% versus 95.7%; p < 0.05). This did not apply to DFS
because there was no local recurrence in the group of N2a. In N3a, 2
of 10 patients experienced a local recurrence. OS was 90.0%, DFS
70.0% in this group (Table 3).
Grading
Recurrence rates and mortality rates differed signiﬁcantly. G3-
tumors had a signiﬁcantly lower survival compared with grade 2
or grade 1 (p < 0.01). 5-years OS was 90.2% for G3, 95.1% for G2 and
100% for G1 (p < 0.01), DFS was 84.2% for G3, 91.9% for G2 and 100%
for G1 (p < 0.001). LRR was incremental with grading: 1.0% for G1-
tumors, 3.5% for G2 and 7.0% for G3 (p < 0.01). Multivariate analysisdemonstrated that G3 was signiﬁcantly associated with lower
survival rates (DFS p < 0.01; OS p < 0.01) (see Fig. 5).
Histopathology
IDC and ILC yielded similar survival rates (OS: IDC vs. LBC 93.8%
vs. 94.8%; p > 0.05; DFS: 94.5% vs. 94.0%; p > 0.05; LRR: 1.7% vs 2.3%;
p > 0.05).
Intrinsic subtypes
TNBC and Her2-positive non luminal subtype had the highest
LRR with 11.3% and 9.3% compared to 2.2% for Luminal A
(p < 0.001). LRR of Luminal B Her2 positive and Luminal B Her2
negative were similar to Luminal Awith 3.8% and 2.7%. Recurrences
of TNBC and Luminal A subtype occurred predominantly in the ﬁrst
2 years. All 4 cases of late relapse (>5 years) were distributed across
all subtypes with the exception of Luminal B Her2 positive. DFS
differed signiﬁcantly in Luminal A and TNBC (DFS 96.3% vs. 87.2%;
p < 0.01), however only as a trend in OS (96.3% vs. 91.3% p ¼ 0.05).
Luminal B Her2 negative BC had a trend to a lower OS, but not in
DFS compared to Luminal A subtype with DFS 94.7% and OS 88.8%
(DFS p ¼ 0.20, OS p ¼ 0.05). Due to a high LRR of Her2 non-luminal
breast cancer, DFS was inferior to Luminal A subtype (90.9% vs.
96.3%; p < 0.01); however OS was not signiﬁcantly differing (93.7%
vs. 96.3%; p ¼ 0.16). The outcome of Luminal B Her2 positive sub-
type was similar to Luminal A (DFS 96.0% p ¼ 0.22; OS 95.4%;
p ¼ 0.36) (see Fig. 6).
Resection margins
All recurrences in our cohort were in cases of surgery with
clear margins (38/910; LRR 4.2%). We identiﬁed 14 resections
with unclear margins. There was no signiﬁcant difference in OS
and DFS in both groups (OS R0 94.6% vs. 90.3%; p > 0.05; DFS R0
94.4% vs R1 100%; p ¼ 0.4). In 20 cases there was no information
on further resection of unclear margins. Factors included in
multivariate regression analysis are compiled in Table 4
(supplement.material).
Discussion
The median age of our cohort of 944 primary unilateral BC was
at 57.6 years approximately 7.5 years lower than generally in Ger-
many [8]. Although in the present study there were no signiﬁcant
differences in local recurrence rates, DFS and OS between the age
groups of <40 years and over 40 years, in several studies age has
been conﬁrmed as an independent prognostic factor. Miles R.
et al.(2012) found a lower 5 year-RFS (recurrence-free-survival) in
patients < 40 years compared with patients  40 years (p < 0.01),
but not a lower OS. HanW. and also other study groups found a cut-
off at 35 years for age as an independent risk factor in breast BC
[9e12] with signiﬁcant lower DFS and OS. LoiblS. et al. also
described higher LRR after neoadjuvant chemotherapy with a cut-
off at 35 years, but not a lower mortality rate [13].
Fig. 5. a: OS according to grading in multivariate analysis (OS p < 0.01). b: DFS according to grading in multivariate analysis (DFS p ¼ 0.004).
M. Rezai et al. / The Breast 24 (2015) 384e390388In this study, we found the highest LRR among non-invasive
tumors (6.4%). The LRR increased gradually in our cohort of pre-
dominantly T1 and T2-tumors with the extent of tumor size,
however this did not achieve statistical signiﬁcance (T1b 1.8%, T1c
3.6%, T2 4.3%). Surprisingly, we identiﬁed a high recurrence rate of
7.1% in pT1a (2/28 pts.) tumors. Both recurrences originated from
G3 and triple-negative BC, respectively Her2 non luminal tumors.
Nevertheless, the 5year-OS of pTis and pT1a was still high with 98%
and 100%.
Unlike the ﬁndings in our study, Rausei S. et al. found a reduced
OS with increasing tumor size (5-year-OS T0-T1 99.0% versus T3
85.4% and T4 86.9%, p < 0.001) [14]. Botteri E. et al. showed that risk
of distant metastases and mortality increased with tumor size
(p < 0.01) [15]. Wapnir IL.et al. reported from 5-NSABP node pos-
itive adjuvant BC trials that tumor size over 2.1 cm represents a
higher risk for in-breast-true recurrence (IBTR) [16].
The nodal status is a recognized prognostic factor. According to
Hernandez-Aya L.F. et al., OS and RFS signiﬁcantly decreased withFig. 6. a: OS according to intrinsic subtypes (p < 0.001)extent of lymph node involvement. In pairwise comparison, only
N2/N3 showed a signiﬁcant worse survival compared with N0,
contrary to N1 versus N0 where no differences were detected [17].
This corresponds well with the ﬁndings in our study.
Grading has already been conﬁrmed early as signiﬁcant prog-
nostic factor [17,18]. After histopathological approximation of
intrinsic subtypes according to 2011 St. Gallen criteria [6], we
explored recurrences in our cohort and found them to correspond
with the cohort of intrinsic subtypes of Sørlie et al. (2001) [1]. TNBC
in our cohort had a higher recurrence (LRR 11.3%) compared with
those published by Hattangadi-Gluth J. et al. (2012) [19], with LRR
in a similar cohort with T1-T2/N0-3 tumors and 5-y-FU of Luminal
A 0.2%, Her2 9.0%, basal-like (triple-negative) 4.4% (p < 0.0001)
[20]. TNBC had a markedly lower survival rate. Wang Y et al. (2011)
had similar results in their study. We also conﬁrmed this in a
previous study of a large cancer registry [21].
Of note, Luminal B HER2 negative BC had a trend to lower sur-
vival in our cohort compared with international data. This may be. b: DFS according to intrinsic subtypes (p < 0.001).
M. Rezai et al. / The Breast 24 (2015) 384e390 389explained by the uniform poor differentiation (G3) in this
subgroup.
There was no signal of over-representation of any intrinsic
subtype in the group of tumors with unclear margins (n¼ 108). We
found that intrinsic subtype is not a predictor for unclear margins
(p > 0.05). This issue has not been speciﬁcally addressed before in
international literature, whereas some studies have put emphasis
on the fact that intrinsic subtypes are prognostic for nodal
involvement or other histopathological features as Jones T et al.
have published in a case cohort study (2013) [22].
This study encourages surgeons to breast conservation because
it shows that type of oncoplastic surgery does not need to vary with
intrinsic subtypes as all intrinsic subtypes may be dealt with breast
preservation at a high level of local oncological safety. Speciﬁc BC
subtypes do not bear a higher risk of recurrence due to their mul-
ticentricity or other clinico-pathological features like tumor size at
diagnosis or nodal involvement but due to their early systemic
spread and local recurrence even after mastectomy.
The histological subtypes e invasive-ductal and lobular e did
not exert any impact on different local control or survival. Arpino G.
et al. (2004) demonstrated the same results in a earlier study at a 5-
y-FU (ILC vs. IDC: DFS 85.7% vs. 83.5%, p ¼ 0.13; OS 85.6% vs. 84.1%
p ¼ 0.64) [23]. Lee J eH. et al. (2010) conﬁrmed this ﬁnding at a 10-
years-FU [24]. Pestalozzi B.C. et al. demonstrated a prognostic
advantage of ILC only for the ﬁrst years. In the following 6e10 years
of IDC, prognosis was superior to ILC [24]. With regard to the pa-
tient population, the Korean cohort published by Lee J.-H. et al., our
subgroup of ILC included more HR positive and Her2 enriched tu-
mors [24]. Arpino G. et al. and Pestalozzi B.C et al., had older pa-
tients with ILC, the tumors were larger than the IDC and had a
higher grading [23,25]. In our study population, there were no
differences in the representation of ILC in the age groups, intrinsic
subgroups, different tumor sizes and nodal status. As to the grading,
the IDC had more G3-tumors with 23.0% compared with ILC
(2.7%).Clearness of margins did not convey a substantial survival
beneﬁt under multimodal treatment in our study. Lobular histology
was not associated with a higher rate of unclear margins, recur-
rence or mortality than invasive-ductal histology. Whereas
increasing T-size did not correlate with an inferior survival, tumor
biology according to intrinsic subtypes was governing the fate of
the local control of the study population. In this study, the majority
of patients presentedwith T1/T2 stages, which reﬂects the situation
of modern, early detection of breast cancer.
Conclusion
This study of more than 1000 oncoplastic patients may serve as
a translation of the concept of intrinsic subtypes into the frame-
work of oncoplastic surgery, and furthermore deciphers the
following principles relevant for oncoplastic surgery:
 T1 and T2 tumor stages do not differ signiﬁcantly in prognosis
and low lymph node involvement is comparable to no lymph
node involvement.
 Type of oncoplastic surgery does not vary with intrinsic subtype.
 Lobular histology and multifocal/multicentric DCIS are pre-
dictors of secondary mastectomy, but do not convey any impact
on overall survival.
 Local recurrences are a variable of intrinsic subtypes with triple
negative breast cancer and non luminal Her2 enriched breast
cancer at highest risk of recurrence. A larger extent of surgery
may not overcome a higher intrinsic risk.
 Multimodal treatment and oncoplastic surgery with resections
of a median of 32 g in a cohort of predominantly T1/T2-tumors
provides a high level of local control and survival.Ethical approval
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